{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:10:10Z","timestamp":1768871410662,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11739-021-02651-w","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T18:37:00Z","timestamp":1613673420000},"page":"1793-1802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities"],"prefix":"10.1007","volume":"16","author":[{"given":"Antonella","family":"Caminati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Madotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Cesana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Harari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"2651_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/ajrccm.157.1.9704130","volume":"157","author":"JA Bjoraker","year":"1998","unstructured":"Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199\u2013203","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR2","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1164\/ajrccm.162.6.2003049","volume":"162","author":"AG Nicholson","year":"2000","unstructured":"Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213\u20132217","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1183\/09031936.02.00182002","volume":"19","author":"KR Flaherty","year":"2002","unstructured":"Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19:275\u2013283","journal-title":"Eur Respir J"},{"key":"2651_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1183\/16000617.0042-2015","volume":"24","author":"S Harari","year":"2015","unstructured":"Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real life experience. Eur Respir Rev 24:420\u2013427","journal-title":"Eur Respir Rev"},{"key":"2651_CR5","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ,\u00a0Behr J,\u00a0Brown KK, et al (2011) ATS\/ERS\/JRS\/ALAT committee on idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788\u2013824"},{"issue":"3","key":"2651_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/rccm.200701-044OC","volume":"176","author":"AL Olson","year":"2007","unstructured":"Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK (2007) Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 176(3):277\u2013284","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2651_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1378\/chest.09-1002","volume":"137","author":"ER Fern\u00e1ndez P\u00e9rez","year":"2010","unstructured":"Fern\u00e1ndez P\u00e9rez ER, Daniels CE, Schroeder DR, St SJ, Hartman TE, Bartholmai BJ et al (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137(1):129\u2013137","journal-title":"Chest"},{"issue":"1","key":"2651_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1378\/chest.10-2572","volume":"140","author":"SD Nathan","year":"2011","unstructured":"Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E et al (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140(1):221\u2013229","journal-title":"Chest"},{"issue":"4","key":"2651_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1378\/chest.12-0298","volume":"142","author":"AW Brown","year":"2012","unstructured":"Brown AW, Shlobin OA, Weir N, Albano MC, Ahmad S, Smith M et al (2012) Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. Chest 142(4):1005\u20131010","journal-title":"Chest"},{"key":"2651_CR10","doi-asserted-by":"crossref","unstructured":"Raghu G, Brown KK, Bradford WZ, Starko K,\u00a0Noble PW,\u00a0Schwartz DA,\u00a0et al (2004) Idiopathic pulmonary fibrosis study group. A placebo-controlled trialof interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2):125\u2013133","DOI":"10.1056\/NEJMoa030511"},{"key":"2651_CR11","doi-asserted-by":"crossref","unstructured":"King TE Jr, Albera C, Bradford WZ, Costabel U,\u00a0Hormel P,\u00a0Lancaster L,\u00a0et al (2009) INSPIRE Study Group. Effect of interferon gamma-1b on survival inpatients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374 (9685):222\u2013228","DOI":"10.1016\/S0140-6736(09)60551-1"},{"issue":"1","key":"2651_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","volume":"177","author":"TE King Jr","year":"2008","unstructured":"King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al (2008) BUILD-1: a randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75\u201381","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2651_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","volume":"184","author":"TE King Jr","year":"2011","unstructured":"King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F et al (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(1):92\u201399","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR14","doi-asserted-by":"crossref","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U,\u00a0Glassberg MK,\u00a0Kardatzke D, et al (2011) CAPACITY Study Group. Pirfenidonein patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377 (9779):1760\u20131769","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2651_CR15","doi-asserted-by":"crossref","unstructured":"Raghu G, Behr J, Brown KK, Egan JJ,\u00a0Kawut SM,\u00a0Flaherty KR, et al (2013) ARTEMIS-IPF investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158 (9):641\u2013649","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"issue":"10","key":"2651_CR16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.201201-0006PP","volume":"185","author":"G Raghu","year":"2012","unstructured":"Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr et al (2012) Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185(10):1044\u20131048","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2651_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","volume":"186","author":"I Noth","year":"2012","unstructured":"Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al (2012) Idiopathic pulmonary fibrosis clinical research network (IPFnet) A placebo controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88\u201395","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR18","doi-asserted-by":"crossref","unstructured":"Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ (2012) Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 (21): 1968\u20131977","DOI":"10.1056\/NEJMoa1113354"},{"key":"2651_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Moises S, Kim DS, Hansell DM, Nicholson AG et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079\u20131087","journal-title":"N Engl J Med"},{"key":"2651_CR20","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082","journal-title":"N Engl J Med"},{"issue":"5","key":"2651_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1378\/chest.14-0492","volume":"146","author":"HR Collard","year":"2014","unstructured":"Collard HR, Brown KK, Martinez JJ, Raghu G, Roberts RS, Anstrom KJ (2014) Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest 146(5):1256\u20131262","journal-title":"Chest"},{"issue":"137","key":"2651_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1183\/16000617.0042-2015","volume":"24","author":"S Harari","year":"2015","unstructured":"Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 24(137):420\u2013427","journal-title":"Eur Respir Rev"},{"key":"2651_CR23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","volume":"174","author":"G Raghu","year":"2006","unstructured":"Raghu G, Weycher D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810\u2013816","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1136\/thx.2006.062836","volume":"61","author":"J Gribbin","year":"2006","unstructured":"Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980\u2013985","journal-title":"Thorax"},{"key":"2651_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1440-1843.2008.01349.x","volume":"13","author":"S Ohno","year":"2008","unstructured":"Ohno S, Nakaya T, Bando M, Sugyma Y (2008) Idiopathic pulmonary fibrosis\u2014results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 13:926\u2013928","journal-title":"Respirology"},{"key":"2651_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/thx.2010.148031","volume":"66","author":"V Navaratnam","year":"2011","unstructured":"Navaratnam V, Fleming KM, West J, Smith CJP, Jenkins RG, Fogarty A, Hubbard RB (2011) The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 66:462\u2013467","journal-title":"Thorax"},{"key":"2651_CR27","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.rmed.2012.07.012","volume":"106","author":"CC Lai","year":"2012","unstructured":"Lai CC, Wang C-Y, Lu H-M, Chen L, Teng N-C, Yan Y-H et al (2012) Idiopathic pulmonary fibrosis in Taiwan\u2014a population-based study. Respir Med 106:1566\u20131574","journal-title":"Respir Med"},{"key":"2651_CR28","doi-asserted-by":"publisher","first-page":"e0147072","DOI":"10.1371\/journal.pone.0147072","volume":"11","author":"S Harari","year":"2016","unstructured":"Harari S, Madotto F, Caminati A, Conti S, Cesana GC (2016) Epidemiology of idiopathic pulmonary fibrosis in Northern Italy. PLoS ONE 11:e0147072","journal-title":"PLoS ONE"},{"key":"2651_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1183\/13993003.01653-2015","volume":"48","author":"G Raghu","year":"2016","unstructured":"Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR (2016) Incidence and prevalence of idiopathic pulmonary fibrosis in US adult 18\u201364 years old. Eur Respir J 48:179\u2013186","journal-title":"Eur Respir J"},{"key":"2651_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/CEOR.S154323","volume":"10","author":"JE Tarride","year":"2018","unstructured":"Tarride JE, Hopkins RB, Burke N, Guertin JR, O\u2019Reilly D, Fell CD et al (2018) Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Clinicoecon Outcomes Res 10:127\u2013137","journal-title":"Clinicoecon Outcomes Res"},{"key":"2651_CR31","doi-asserted-by":"crossref","unstructured":"Esposito DB, Lanes D, Donneyong M, Holick CN,\u00a0Lasky JA,\u00a0Lederer D, et al (2015) Idiopathic pulmonary fibrosis in United States Automated Claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med 192(10):1200\u20131207","DOI":"10.1164\/rccm.201504-0818OC"},{"key":"2651_CR32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/01621459.1969.10501049","volume":"64","author":"IP Fellegi","year":"1969","unstructured":"Fellegi IP, Sunter AB (1969) A theory for record linkage. J Am Stat Assoc 64:1183\u20131210","journal-title":"J Am Stat Assoc"},{"key":"2651_CR33","unstructured":"Newcombe HB (1988) Handbook of record linkage: methods for health and statistical studies, administration, and business. Oxford University Press, Incorporate"},{"key":"2651_CR34","first-page":"79","volume":"32","author":"C Fornari","year":"2008","unstructured":"Fornari C, Madotto F, Demaria M, Romanelli A, Pepe P, Raciti M et al (2008) Record-linkage procedures in epidemiology: an Italian multicentre study. Epidemiol Prev 32:79\u201388","journal-title":"Epidemiol Prev"},{"issue":"7","key":"2651_CR35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee Y-C, Collard HR (2014) Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence prevalence and survival 2001\u201311. Lancet Respir Med 2(7):566\u2013572","journal-title":"Lancet Respir Med"},{"key":"2651_CR36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1513\/AnnalsATS.201610-764OC","volume":"14","author":"B Ley","year":"2017","unstructured":"Ley B, Urbania T, Husson G, Vittinghoff E, Brush DR, Eisner MD et al (2017) Code-based diagnostic algorithms for idiopathic pulmonary fibrosis. Case validation and improvement. Ann Am Thorac Soc 14:880\u2013887","journal-title":"Ann Am Thorac Soc"},{"key":"2651_CR37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139","journal-title":"Med Care"},{"key":"2651_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"2651_CR39","unstructured":"David S (2007) Handbook of parametric and nonparametric statistical procedures. Ed. Chapman & Hall\/CRC (4th edition)."},{"key":"2651_CR40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684\u2013691","journal-title":"Ann Intern Med"},{"issue":"3","key":"2651_CR41","doi-asserted-by":"publisher","first-page":"1801587","DOI":"10.1183\/13993003.01587-2018","volume":"53","author":"SE Torrisi","year":"2019","unstructured":"Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C (2019) The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study. Eur Respir J 53(3):1801587","journal-title":"Eur Respir J"},{"issue":"3","key":"2651_CR42","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T et al (2016) Impact of comorbidities on mortality inpatients with idiopathic pulmonary fibrosis. PLoS ONE 11(3):e0151425","journal-title":"PLoS ONE"},{"key":"2651_CR43","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1164\/ajrccm.153.5.8630600","volume":"153","author":"DM Mannino","year":"1996","unstructured":"Mannino DM, Etzel RA, Parrish RG (1996) Pulmonary fibrosis deaths in the United States, 1979\u20131991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 153:1548\u20131552","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431\u2013440","journal-title":"Am J Respir Crit Care Med"},{"key":"2651_CR45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1183\/09031936.00165207","volume":"31","author":"MK Han","year":"2008","unstructured":"Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J et al (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183\u20131188","journal-title":"Eur Respir J"},{"key":"2651_CR46","doi-asserted-by":"crossref","unstructured":"Collard HR, Chen SY, Yeh WS, Li Q,\u00a0Lee Y-C,\u00a0Wang A,\u00a0Raghu G (2015) Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12(7): 981\u2013987","DOI":"10.1513\/AnnalsATS.201412-553OC"},{"key":"2651_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12890-015-0165-1","volume":"16","author":"K Raimundo","year":"2016","unstructured":"Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ (2016) Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. PBM Pulm Med 16:2","journal-title":"PBM Pulm Med"},{"issue":"2","key":"2651_CR48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathicpulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37(2):356\u2013363","journal-title":"Eur Respir J"},{"key":"2651_CR49","doi-asserted-by":"crossref","unstructured":"Martinez FJ, Safrin S, Weycker D, Starko KM,\u00a0Bradford WZ,\u00a0King TE Jr,\u00a0et al (2005) IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (12pt 1):963\u2013967","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00005"},{"issue":"4","key":"2651_CR50","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A et al (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(4):459\u2013466","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2651_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1378\/chest.13-2424","volume":"147","author":"AW Brown","year":"2015","unstructured":"Brown AW, Fischer CP, Shlobin OA, Buhr RG, Shahzad Ahmad S, Weir NA, Nathan SD (2015) Outcomes after hospitalization in idiopathic pulmonary fibrosis. A cohort study. Chest 147(1):173\u2013179","journal-title":"Chest"},{"key":"2651_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","volume":"194","author":"B Ley","year":"2016","unstructured":"Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR (2016) Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 194:711\u2013718","journal-title":"Am J Respir Crit Care Med"},{"issue":"153","key":"2651_CR53","doi-asserted-by":"publisher","first-page":"190044","DOI":"10.1183\/16000617.0044-2019","volume":"28","author":"A Caminati","year":"2019","unstructured":"Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O et al (2019) Comorbidities on IPF: an underestimated issue. Eur Respir Rev 28(153):190044","journal-title":"Eur Respir Rev"},{"issue":"4","key":"2651_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.rmed.2014.01.008","volume":"108","author":"C Hyldgaard","year":"2014","unstructured":"Hyldgaard C, Hilberg O, Bendstrup E (2014) How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 108(4):647\u2013653","journal-title":"Respir Med"},{"key":"2651_CR55","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1183\/16000617.0040-2015","volume":"24","author":"A Caminati","year":"2015","unstructured":"Caminati A, Madotto F, Cesana GC, Conti S, Harari S (2015) Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 24:436\u2013444","journal-title":"Eur Respir Rev"},{"issue":"7","key":"2651_CR56","first-page":"A600","volume":"17","author":"J Behr","year":"2014","unstructured":"Behr J, Wirtz H, Pittrow D et al (2014) Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: follow-up results of the INSIGHTS-IPF Registry. Eur Respir J 17(7):A600","journal-title":"Eur Respir J"},{"key":"2651_CR57","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02279-2019","author":"J Behr","year":"2020","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M et al (2020) Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02279-2019","journal-title":"Eur Respir J"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-021-02651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-021-02651-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-021-02651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T14:25:33Z","timestamp":1633875933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-021-02651-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2651"],"URL":"https:\/\/doi.org\/10.1007\/s11739-021-02651-w","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]},"assertion":[{"value":"21 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AC reports personal fees from Roche and Boehringer Ingelheim. FM, SC, GCC and LM have nothing to declare. SH reports personal fees from Roche, Actelion and Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Not applicable. This is a retrospective observational study using healthcare administrative data","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}